Frank Diamond
Managing Editor
MANAGED CARE January 2012. ©MediMedia USA

Those who choose these plans tend to be more educated and dedicated to maintaining healthy lifestyles

Managing Editor

The Employee Benefit Research Institute recently went looking for what many hope to be one of the bulwarks of a new, cost-effective health care system — the “engaged consumer.” The institute found him in two relatively new benefit systems: consumer-directed health plans (CDHPs) and high-deductible health plans (HDHPs).

In its “Consumer Engagement in Health Care Survey, 2011,” the EBRI conducted an online poll of 4,703 privately insured adults, ages 21–64, to find out how well CDHPs and HDHPs were doing in the marketplace. It also weighed “the impact of these plans and consumer engagement more generally on the behavior and attitudes of adults with private health insurance coverage.”

Growth

Seven percent of the population was in a CDHP, up from 5 percent in 2010. That’s a 40 percent increase in one year. Enrollment in HDHPs grew from 14 percent to 16 percent. “Overall, 15.8 million adults ages 21–64 with private insurance, representing 13.1 percent of that market, were either in a CDHP or were in an HDHP that was eligible for an HSA....” the survey states. “When their children are counted, about 21 million individuals with private insurance, representing about 12 percent of the market, were either in a CDHP or an HSA-eligible plan.”

This is not only a slight shift in coverage, but in attitude as well. “It is clear that underlying characteristics of the populations enrolled in these plans are different....” For instance, those in CDHPs and HDHPs tend to be more highly educated. In addition, “Adults in CDHPs and HDHPs were significantly less likely to smoke than were adults in traditional plans, and they were significantly more likely to exercise.”

Wellness programs seem to matter more to those enrolled in a CDHP. “CDHP enrollees were more likely than traditional plan enrollees to report that they had the opportunity to fill out a health risk assessment and they were also more likely to report that they had access to a health promotion program.”

Members’ cost-conscious decision making by type of plan, 2011

Employer offers wellness program, 2011

Person participates in wellness program offered by employer, 2011

Though CDHPs and HDHPs are growing, market penetration remains relatively small. EBRI reports that “the amount of time individuals have been in these plans is shorter than the time others have been enrolled in traditional coverage.”

Number of years covered by current health plan, 2011

Of course, a lot of people still don’t know about CDHPs and HDHPs. In particular, someone enrolled in a traditional health plan is not likely to be aware of consumer-directed health plans.

Familiarity with consumer-directed health plans

One of the survey’s conclusions is that “as the CDHP and HDHP markets continue to expand and more enrollees are enrolled for longer periods of time, the sustained impact that these plans are having on cost, quality, and access to health care services will be better understood.”

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.